157 related articles for article (PubMed ID: 17626246)
1. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
[TBL] [Abstract][Full Text] [Related]
2. MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
Tovar C; Higgins B; Kolinsky K; Xia M; Packman K; Heimbrook DC; Vassilev LT
Mol Cancer; 2011 May; 10():49. PubMed ID: 21539745
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth.
Wolff DW; Xie Y; Deng C; Gatalica Z; Yang M; Wang B; Wang J; Lin MF; Abel PW; Tu Y
Int J Cancer; 2012 Apr; 130(7):1521-31. PubMed ID: 21500190
[TBL] [Abstract][Full Text] [Related]
4. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion.
Li Y; Wang L; Zhang M; Melamed J; Liu X; Reiter R; Wei J; Peng Y; Zou X; Pellicer A; Garabedian MJ; Ferrari A; Lee P
Cancer Res; 2009 Apr; 69(8):3332-8. PubMed ID: 19351848
[TBL] [Abstract][Full Text] [Related]
5. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Yoshikawa Y; Stopsack KH; Wang XV; Chen YH; Mazzu YZ; Burton F; Chakraborty G; Rajanala SH; Hirani R; Nandakumar S; Lee GM; Frank D; Davicioni E; Liu G; Carducci MA; Azuma H; Kantoff PW; Sweeney CJ
Mol Oncol; 2022 Dec; 16(22):3994-4010. PubMed ID: 36087093
[TBL] [Abstract][Full Text] [Related]
6. Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo.
Kobayashi T; Inoue T; Shimizu Y; Terada N; Maeno A; Kajita Y; Yamasaki T; Kamba T; Toda Y; Mikami Y; Yamada T; Kamoto T; Ogawa O; Nakamura E
Mol Endocrinol; 2010 Apr; 24(4):722-34. PubMed ID: 20203103
[TBL] [Abstract][Full Text] [Related]
7. Loss of mir-146a function in hormone-refractory prostate cancer.
Lin SL; Chiang A; Chang D; Ying SY
RNA; 2008 Mar; 14(3):417-24. PubMed ID: 18174313
[TBL] [Abstract][Full Text] [Related]
8. Androgen depletion induces senescence in prostate cancer cells through down-regulation of Skp2.
Pernicová Z; Slabáková E; Kharaishvili G; Bouchal J; Král M; Kunická Z; Machala M; Kozubík A; Souček K
Neoplasia; 2011 Jun; 13(6):526-36. PubMed ID: 21677876
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.
Harris WP; Mostaghel EA; Nelson PS; Montgomery B
Nat Clin Pract Urol; 2009 Feb; 6(2):76-85. PubMed ID: 19198621
[TBL] [Abstract][Full Text] [Related]
10. Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.
Nalla AK; Williams TF; Collins CP; Rae DT; Trobridge GD
Mol Carcinog; 2016 Nov; 55(11):1761-1771. PubMed ID: 26512949
[TBL] [Abstract][Full Text] [Related]
11. Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.
Utter M; Chakraborty S; Goren L; Feuser L; Zhu YS; Foster DA
Cancer Lett; 2018 Jun; 423():28-35. PubMed ID: 29524555
[TBL] [Abstract][Full Text] [Related]
12. Rationale for the development of alternative forms of androgen deprivation therapy.
Kumari S; Senapati D; Heemers HV
Endocr Relat Cancer; 2017 Aug; 24(8):R275-R295. PubMed ID: 28566530
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the complexities of androgen receptor signaling in prostate cancer cells.
Heemers HV; Tindall DJ
Cancer Cell; 2009 Apr; 15(4):245-7. PubMed ID: 19345321
[TBL] [Abstract][Full Text] [Related]
14. Supraphysiologic Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer.
Kumar R; Mendonca J; Owoyemi O; Boyapati K; Thomas N; Kanacharoen S; Coffey M; Topiwala D; Gomes C; Ozbek B; Jones T; Rosen M; Dong L; Wiens S; Brennen WN; Isaacs JT; De Marzo AM; Markowski MC; Antonarakis ES; Qian DZ; Pienta KJ; Pardoll DM; Carducci MA; Denmeade SR; Kachhap SK
Cancer Res; 2021 Dec; 81(23):5948-5962. PubMed ID: 34645612
[TBL] [Abstract][Full Text] [Related]
15. Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy.
Guo Y; Wu J; Chen L; Liu L; Bi T; Pan Y; Meng QF; Wang C; Rao L; Li Q
J Nanobiotechnology; 2024 Apr; 22(1):192. PubMed ID: 38637848
[TBL] [Abstract][Full Text] [Related]
16. Intermittent Androgen Deprivation for Biochemically Recurrent Prostate Cancer: First Do No Harm.
Serritella AV; Fenton SE; Hussain M
Eur Urol Focus; 2023 May; 9(3):407-408. PubMed ID: 36707276
[TBL] [Abstract][Full Text] [Related]
17. Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells.
Otsuka T; Hamada A; Iguchi K; Usui S; Hirano K
Biomed Rep; 2013 Jul; 1(4):614-618. PubMed ID: 24648996
[TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy caused a drastic proliferation of B-cell lymphoma with IgG4-related disease in patients with prostate cancer: a case report.
Sasagawa H; Numakura K; Mori M; Kobayashi M; Kashima S; Yamamoto R; Nara T; Saito M; Narita S; Nanjo H; Habuchi T
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15091-15094. PubMed ID: 37688628
[TBL] [Abstract][Full Text] [Related]
19. Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer.
Nordeen SK; Su LJ; Osborne GA; Hayman PM; Orlicky DJ; Wessells VM; van Bokhoven A; Flaig TW
Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575033
[TBL] [Abstract][Full Text] [Related]
20. Characterization of iPS87, a prostate cancer stem cell-like cell line.
Assoun EN; Meyer AN; Jiang MY; Baird SM; Haas M; Donoghue DJ
Oncotarget; 2020 Mar; 11(12):1075-1084. PubMed ID: 32256979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
